Loading...
OTCM
USRM
Market cap64kUSD
Jun 04, Last price  
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
-95.00%
IPO
-100.00%
Name

US Stem Cell Inc

Chart & Performance

D1W1MN
P/E
P/S
0.78
EPS
Div Yield, %
Shrs. gr., 5y
13.87%
Rev. gr., 5y
-56.91%
Revenues
82k
-59.13%
46,00086,000135,350105,503312,80957,051359,80046,38317,47561,10996,0852,055,8312,191,1773,083,2615,520,5376,700,8883,072,293277,087200,74982,049
Net income
-3m
L-22.91%
-6,038,000-5,519,000-7,326,557-13,180,646-18,067,084-14,204,925-3,844,249-5,159,456-4,697,037-4,016,467-3,143,259-2,253,511-1,641,880-2,070,386-3,481,491-2,160,427-5,035,130-3,378,862-4,287,564-3,305,425
CFO
-305k
L-71.18%
-5,765,455-7,829,497-9,729,081-10,979,029-2,026,200-1,894,245-1,693,904-1,095,276-1,913,326-1,108,647-844,690112,2421,231,393602,467-1,210,994-478,886-1,057,939-304,852

Profile

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.
IPO date
Feb 19, 2008
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
82
-59.13%
Cost of revenue
24
Unusual Expense (Income)
NOPBT
58
NOPBT Margin
71.03%
Operating Taxes
447
Tax Rate
767.79%
NOPAT
(389)
Net income
(3,305)
-22.91%
Dividends
Dividend yield
Proceeds from repurchase of equity
85
BB yield
-2.99%
Debt
Debt current
8,265
Long-term debt
682
Deferred revenue
54
Other long-term liabilities
54
Net debt
8,942
Cash flow
Cash from operating activities
(305)
CAPEX
Cash from investing activities
Cash from financing activities
271
FCF
662
Balance
Cash
5
Long term investments
Excess cash
1
Stockholders' equity
(141,883)
Invested Capital
136,191
ROIC
ROCE
EV
Common stock shares outstanding
591,558
Price
0.00
-20.00%
Market cap
2,839
2.70%
EV
11,781
EBITDA
744
EV/EBITDA
15.84
Interest
690
Interest/NOPBT
1,183.86%